Hypothyroidism and Fatty Liver Disease: Beyond NASH

Hypothyroidism is independently associated with NAFLD/MASLD and accelerates progression to fibrosis. Correcting thyroid status reduces liver fat in most patients. Resmetirom — a liver-selective T3 receptor agonist — is the first approved drug for MASH and is separate from levothyroxine.

Why hypothyroidism promotes fatty liver

The liver is one of the most thyroid-hormone-sensitive organs in the body. T3 acting through the thyroid hormone receptor beta (TR-β) drives three lipid-handling programs at once [C6]:

• Hepatic beta-oxidation — burning fatty acids inside mitochondria for energy
• De novo lipogenesis — converting carbohydrates into new fat
• Mitochondrial biogenesis and turnover — keeping the cellular machinery healthy

When thyroid hormone falls, beta-oxidation drops, lipogenesis rises (driven by SREBP-1c and ChREBP), and mitochondria become less efficient at clearing the resulting triglyceride load [C6]. Fat accumulates inside hepatocytes — the defining feature of NAFLD (now called MASLD, metabolic dysfunction-associated steatotic liver disease).

Hypothyroidism also worsens insulin resistance, raises LDL cholesterol, and slows lipoprotein clearance — all of which feed back into the liver and amplify steatosis [C3][C7]. This is why fatty liver in hypothyroid patients tends to track with the broader metabolic picture: weight gain, dyslipidemia, and elevated insulin levels.

The clinical pattern and epidemiology

Multiple systematic reviews and meta-analyses report that hypothyroidism — including the subclinical form — roughly doubles the prevalence of NAFLD compared with euthyroid controls, and is associated with more advanced fibrosis stages [C3][C4]. In adolescents with obesity, even mild thyroid dysfunction tracks with higher rates of fatty liver [C3][C4].

What this looks like clinically:

• Mildly elevated ALT and AST on routine labs, often the first clue
• Steatosis on ultrasound or MRI in someone with a metabolic risk profile
• High LDL cholesterol and triglycerides, often out of proportion to diet
• Slower-than-expected response to lifestyle changes for weight or lipids

MASLD itself has extrahepatic consequences — cardiovascular disease, chronic kidney disease, and sleep-disordered breathing all cluster with it [C7]. That is part of why correcting any contributing endocrine driver, including hypothyroidism, matters beyond the liver itself.

What recovers on adequate levothyroxine

Restoring thyroid hormone with levothyroxine restarts the lipid-burning programs in the liver. The reported timeline in observational data and small interventional studies [C1][C3]:

• Weeks 4–8: LDL cholesterol and triglycerides begin to fall as TSH normalizes
• Months 3–6: ALT/AST often trend down; insulin sensitivity improves
• Months 6–12: Liver fat on imaging decreases in many patients, especially those who also lose weight

Levothyroxine is not a MASH drug — it does not specifically target advanced steatohepatitis or fibrosis. But adequate replacement removes hypothyroidism as a contributor to fat accumulation, which is the first thing your endocrinologist will check when fatty liver appears alongside a high TSH [C1][C8].

When fatty liver persists despite normal TSH

Several scenarios explain ongoing steatosis even after thyroid hormone normalizes [C3][C7]:

1. Established metabolic syndrome. Obesity, type 2 diabetes, and insulin resistance drive MASLD independently of thyroid status. Weight loss of 7–10% of body weight is the single most effective intervention for reducing liver fat [C5][C7].
2. Dyslipidemia not fully corrected. Persistent high LDL or triglycerides keep delivering substrate to the liver. Lipid management is its own treatment track.
3. Progression to MASH or fibrosis. Once the disease has progressed beyond simple steatosis to steatohepatitis (inflammation) or fibrosis (scarring), thyroid correction alone does not reverse the damage [C5][C6].
4. Other contributors — alcohol, certain medications (amiodarone, tamoxifen, methotrexate), and viral hepatitis can mimic or coexist with MASLD.
5. Severe sleep apnea, which is more common in hypothyroidism and itself worsens steatosis [C7].

This is where resmetirom enters the picture. It is the first FDA-approved drug for non-cirrhotic MASH with significant fibrosis (F2–F3), acting as a liver-selective TR-β agonist [C5][C6]. By binding TR-β preferentially in hepatocytes, it activates beta-oxidation and reduces de novo lipogenesis without producing systemic hyperthyroidism. The MAESTRO-NASH trials showed both MASH resolution and fibrosis improvement at 52 weeks versus placebo [C5].

Importantly, resmetirom is not a thyroid medication you take instead of levothyroxine. It is a separate therapy for diagnosed MASH, prescribed by hepatology, not endocrinology. See our thyroid-resmetirom-nash article for the full picture.

What does NOT help

Several heavily-marketed approaches lack evidence for thyroid-related fatty liver [C1][C8]:

• "Liver detox" supplements — milk thistle, dandelion, glutathione blends. None have been shown to reduce liver fat in MASLD trials.
• Adding T3 or NDT to "boost liver metabolism." The 2014 ATA guideline recommends levothyroxine as first-line; routine T3 addition is not recommended and over-replacement carries cardiac and bone risk [C1].
• High-dose biotin and B-vitamin "liver support." Biotin interferes with TSH and free T4 assays, complicating dose adjustment.
• Very low-calorie or extreme low-carb diets without supervision. Rapid weight loss can transiently raise transaminases and trigger gallstones.

Practical guidelines

1. Confirm thyroid status if you have NAFLD/MASLD. A TSH and free T4 are reasonable in anyone with unexplained steatosis or elevated transaminases [C1][C8].
2. Get TSH into the normal range first. Most thyroid-driven steatosis improves once TSH is stable in target (often 0.5–2.5 mIU/L) [C1].
3. Pursue 7–10% weight loss if you have excess weight. This is the highest-yield intervention for MASLD and works regardless of thyroid status [C5][C7].
4. Address lipids and glucose. Statins are safe in MASLD and may help; diabetes control reduces fibrosis progression [C7].
5. Recheck liver enzymes 6 months after TSH normalizes. Persistent elevation warrants a hepatology referral and consideration of staging (FibroScan, MRE) [C5][C7].
6. Discuss resmetirom with hepatology — not your endocrinologist — only if you have biopsy- or imaging-confirmed MASH with fibrosis. It is prescribed by liver specialists and requires liver-specific monitoring [C5][C6].

Frequently asked questions

Does levothyroxine reverse fatty liver? We avoid the word "reverse" because the picture is more nuanced. Adequate levothyroxine removes hypothyroidism as a driver of fat accumulation, and most patients see liver fat decrease over 6 to 12 months — but if obesity, diabetes, or dyslipidemia are also present, those need their own treatment [C1][C5].

Is subclinical hypothyroidism enough to cause fatty liver? Observational data suggest yes — even mild thyroid dysfunction is associated with higher NAFLD prevalence and worse metabolic profile, particularly in adolescents and adults with obesity [C3][C4]. Whether to treat subclinical hypothyroidism specifically for liver fat is still debated and is an individual decision with your endocrinologist.

Can I take resmetirom instead of levothyroxine? No. They do different jobs. Levothyroxine replaces missing thyroid hormone systemically. Resmetirom is liver-selective and is approved for MASH with significant fibrosis — not for hypothyroidism [C5][C6]. If you have both conditions, you would be on both.

Will losing weight fix my fatty liver if my TSH is fine? Often, yes. Weight loss of 7–10% reduces liver fat and can improve inflammation. It is the most evidence-supported intervention for MASLD across all subgroups [C5][C7].

Should I get a FibroScan? Talk to your primary care doctor or hepatologist. Non-invasive fibrosis scoring (FIB-4, FibroScan, MRE) is standard for risk-stratifying anyone with MASLD and elevated transaminases [C5][C7].

Bottom line

Hypothyroidism roughly doubles the prevalence of fatty liver disease and accelerates progression toward fibrosis through reduced hepatic beta-oxidation, increased de novo lipogenesis, and mitochondrial dysfunction [C3][C4][C6]. Adequate levothyroxine reduces liver fat in most patients over 6 to 12 months, but it does not treat established MASH or fibrosis [C1][C5]. Resmetirom — the first FDA-approved MASH drug — is a separate, liver-selective T3 receptor agonist prescribed by hepatology for biopsy- or imaging-confirmed MASH, not a substitute for levothyroxine [C5][C6]. Weight loss of 7–10%, lipid control, and glucose control remain the cornerstones across all scenarios [C5][C7].